Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs IQIYI Inc - ADR — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while IQIYI Inc - ADR trades at $1.02 (market cap $974.67M). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 12.9× IQIYI Inc - ADR's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and IQIYI Inc - ADR for 55 Days on average.
| HALO | IQ | |
|---|---|---|
Market Cap | $12.58B | $974.67M |
Volume | 2,179,278 | 4,964,108 |
Sector | Health | Media |
52-Week High | $115.22 | $2.35 |
52-Week Low | $61.63 | $0.86 |
Typical Hold Time | 1 Days | 55 Days |
Enterprise Value | $14.49B | $2.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
iQIYI (IQ) trades at $1.01, down 0.49% with bearish technical signals. The company reported Q2 2026 revenue of $6.3 billion (up 1% sequentially) but posted a net loss of -$206 million for 2025. Analyst consensus is mixed with 50% buy ratings, while technical indicators show bearish momentum with neutral oscillators. Recent developments include the successful launch of AI-generated content series 'The Ferry Man' generating over RMB 8 million in revenue-sharing.
The outlook remains challenging with declining revenue trends and negative profitability, though the company's pivot to AI-driven content production offers potential cost savings. Key risks include streaming business contraction and Chinese regulatory environment. Wall Street maintains cautious optimism with 11 buy ratings but investors should monitor Q3 earnings for turnaround evidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
